Nitrative stress in cerebral endothelium is mediated by mGluR5 in hyperhomocysteinemia

J Cereb Blood Flow Metab. 2012 May;32(5):825-34. doi: 10.1038/jcbfm.2011.185. Epub 2011 Dec 21.

Abstract

Hyperhomocysteinemia (HHcy) disrupts nitric oxide (NO) signaling and increases nitrative stress in cerebral microvascular endothelial cells (CMVECs). This is mediated, in part, by protein nitrotyrosinylation (3-nitrotyrosine; 3-NT) though the mechanisms by which extracellular homocysteine (Hcy) generates intracellular 3-NT are unknown. Using a murine model of mild HHcy (cbs(+/-) mouse), we show that 3-NT is significantly elevated in cerebral microvessels with concomitant reductions in serum NO bioavailability as compared with wild-type littermate controls (cbs(+/+)). Directed pharmacology identified a receptor-dependent mechanism for 3-NT formation in CMVECs. Homocysteine increased expression of inducible NO synthase (iNOS) and formation of 3-NT, both of which were blocked by inhibition of metabotropic glutamate receptor-5 (mGluR5) with the specific antagonist 2-methyl-6-(phenylethynyl) pyridine hydrochloride. Activation of mGluR5 is both sufficient and necessary to drive the nitrative stress because direct activation using the mGluR5-specific agonist (RS)-2-chloro-5-hydroxyphenylglycine also increased iNOS expression and 3-NT formation while knockdown of mGluR5 receptor expression by short hairpin RNA (shRNA) blocked their increase in response to Hcy. Nitric oxide derived from iNOS was required for Hcy-mediated formation of 3-NT because the effect was blocked by 1400W. These results provide the first evidence for a receptor-dependent process that explains how plasma Hcy levels control intracellular nitrative stress in cerebral microvascular endothelium.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amidines / pharmacology
  • Animals
  • Benzylamines / pharmacology
  • Brain / blood supply
  • Brain / metabolism*
  • Endothelium / metabolism*
  • Enzyme Inhibitors / pharmacology
  • Excitatory Amino Acid Agonists / pharmacology
  • Gene Expression Regulation, Enzymologic / drug effects
  • Gene Expression Regulation, Enzymologic / genetics
  • Glycine / analogs & derivatives
  • Glycine / pharmacology
  • Homocysteine / genetics
  • Homocysteine / metabolism
  • Hyperhomocysteinemia / genetics
  • Hyperhomocysteinemia / metabolism*
  • Mice
  • Mice, Knockout
  • Nitric Oxide / genetics
  • Nitric Oxide / metabolism*
  • Nitric Oxide Synthase Type II / antagonists & inhibitors
  • Nitric Oxide Synthase Type II / biosynthesis
  • Nitric Oxide Synthase Type II / genetics
  • Phenylacetates / pharmacology
  • Receptor, Metabotropic Glutamate 5
  • Receptors, Metabotropic Glutamate / agonists
  • Receptors, Metabotropic Glutamate / antagonists & inhibitors
  • Receptors, Metabotropic Glutamate / genetics
  • Receptors, Metabotropic Glutamate / metabolism*
  • Stress, Physiological*
  • Tyrosine / analogs & derivatives
  • Tyrosine / genetics
  • Tyrosine / metabolism

Substances

  • 2-chloro-5-hydroxyphenylglycine
  • Amidines
  • Benzylamines
  • Enzyme Inhibitors
  • Excitatory Amino Acid Agonists
  • Grm5 protein, mouse
  • N-(3-(aminomethyl)benzyl)acetamidine
  • Phenylacetates
  • Receptor, Metabotropic Glutamate 5
  • Receptors, Metabotropic Glutamate
  • Homocysteine
  • Nitric Oxide
  • 3-nitrotyrosine
  • Tyrosine
  • Nitric Oxide Synthase Type II
  • Nos2 protein, mouse
  • Glycine